Moderna (MRNA) Q3 2026 Earnings Call Transcript

Moderna reported Q3 revenue of $1.3 billion, up 29% year over year, and net income of $162 million versus a $200 million loss a year earlier; diluted EPS was $0.38 versus a $0.51 loss. Management raised full-year 2026 revenue growth guidance to 15%–25% from up to 10%, lowered adjusted cash-cost guidance by $200 million to $3.8 billion, and projected year-end cash and investments of $8.1 billion–$8.3 billion. The melanoma Phase 3 trial of intismeran plus Keytruda showed a 42% reduction in recurrence or death risk versus Keytruda alone, while the norovirus Phase 3 study missed early-success criteria and Moderna will not enroll an additional cohort this winter. Cash and investments include $2.6 billion in convertible-note net proceeds and reflect a $950 million litigation settlement payment.

Analysis

Moderna’s near-term earnings power is still unusually sensitive to seasonal shipment timing and government/market partnerships, so the raised outlook is a better signal of execution than proof of a durable demand reset. The key second-order question is whether international contracts create repeatable demand and pricing power—or simply shift deliveries across quarters. Verify contract duration, committed versus optional volumes, and 2027 order visibility before capitalizing this growth.

The larger valuation inflection is oncology, not the respiratory quarter. Positive melanoma data could support a new revenue stream and reinforce Keytruda’s adjuvant franchise; Merck may benefit from combination use, but the commercial split and individualized manufacturing economics are undisclosed. Do not extrapolate melanoma efficacy to renal, lung, or pancreatic cancers: those programs remain distinct clinical risks. The upcoming BLA submission and renal-cell readout are nearer-term catalysts; approval and scalable production are 2027-plus questions.

Cash-cost reductions and financing lower near-term liquidity risk, but the $3 billion convertible issuance is not free capital: conversion terms and eventual dilution matter, while capped calls only mitigate dilution within specified limits. The norovirus setback and deferred MMA pivotal decision temper the breadth of the pipeline narrative. Also reconcile the transcript’s inconsistent headline financial figures against the filing before using quarterly estimates.

Contrarian view: the bullish case may over-credit a strong season and partnership shipments as a structural vaccine recovery. Conversely, investors may underweight the value of a randomized Phase 3 oncology result. The November 12 Analyst Day could sharpen manufacturing and commercialization assumptions, but management targets alone do not establish margins or launch economics.

Key Decisions for Investors

• Avoid chasing MRNA solely on the quarterly beat. Treat it as a catalyst-driven long only if the November 12 Analyst Day supports repeatable international orders and credible gross-margin improvement; reduce exposure if fourth-quarter sales prove largely shipment timing or 2027 visibility weakens.
• For a defined-risk event position, consider a small MRNA call spread ahead of the melanoma BLA/renal-cell updates rather than unhedged common stock; size for binary clinical and regulatory risk. The upside case is pipeline repricing, while the downside is renewed seasonal-sales skepticism or a negative RCC readout.
• MRK is a potential lower-beta way to participate in the melanoma combination opportunity, but do not assume Moderna’s economics accrue materially to Merck without partnership disclosures. Reassess on filing terms, launch responsibilities, and evidence that combination use expands rather than merely shifts Keytruda utilization.
• Monitor the convertible’s conversion price/capped-call coverage, Q4 vaccine sell-through versus shipments, and 2027 international contract commitments. These are the missing inputs that determine dilution, revenue durability, and whether the raised outlook warrants a lasting multiple re-rating.